Back to News

2017 IQ Consortium Leadership Transition

2017 IQ Consortium Leadership Transition

December 13, 2016






2017 IQ Leadership Transition

Thank You to Our Outgoing Chair and

Welcome to Our Incoming Chair and Vice-Chair





November 2016



The IQ Consortium has had the good fortune to have been led by strong leaders from its inception in 2010 – leaders with vision, open-minds and moxie. Next month, our current leader Dr. Steve King, will step down and make way for a new Chair. 

Since the beginning of his two-year term in 2014, Steve’s objective for the Consortium was clear: elevate IQ’s position in the pharmaceutical and biotech community by internal growth and external partnership. To that end, Steve led numerous efforts touching nearly every aspect of the organization, including the development of the new IQ strategic plan adopted in 2015, establishment of the Leadership and Working Group fora, support of the formation of the Biologics CMC Leadership Group and DILI (Drug Induced Liver Injury) advocacy for centralized collaboration tools and more robust internal communication, and pursuit of and engagement in more frequent dialogue regarding collaboration with PhRMA. Steve has been tireless in his dedication.  With these initiatives and countless others, his goal has been constant: empower the members and future leaders with the ability to leverage the Consortium’s collective knowledge and influence for the ultimate benefit of patients, regulators and the broader R&D community.  IQ’s continued success is a testament to the achievement of that goal and the legacy that it will leave.

Dr. Pierre Boulas, Director of Analytical Development at Biogen, will begin his two-year term as Chair from 2017 through 2019.  His successor, Dr. Carl McMillian, Vice President of Toxicology at Eli Lilly and Company, will serve as Vice-chair until the close of 2019.  Pierre and Carl have long been members of the IQ Board of Directors who have been highly engaged in IQ activities at both the Board and Executive Committee levels as well as within IQ Leadership Groups. 

Having served as Chair of the IQ Symposium Organizing Committee for three past symposia, Pierre is a staunch proponent of the positive disruptive innovation needed within the industry to address current development roadblocks and regulatory hurdles.  His significant experience navigating discussions focusing on CMC specific matters as well as those targeting Life Sciences more broadly, highlights Pierre’s suitability to lead the Consortium as we begin to close out the first score of the 21st century.

“The best hope… of the pharmaceutical industry,” is how Carl characterized the IQ Consortium.  Carl’s involvement in the Drug Metabolism Leadership Group as well as the IQ Planning Committee has afforded him a deep appreciation for the talented members within IQ who are dealing with the pharmaceutical industry’s highly regulated environment.  He believes that by harnessing the power of the energy, expertise and relationships as the Consortium continues to proactively nurture collaborative discussions and activities with regulators and professional societies, IQ will more firmly establish itself as the principal organization representing pharmaceutical development.

Please join us in thanking Steve for his stewardship of the Consortium and welcoming Pierre and Carl to the helm.



Our Mission: The IQ Consortium is dedicated to augmenting the capability of member companies to develop transformational solutions that benefit patients, regulators and the broader R&D community.